Managing homozygous familial hypercholesterolaemia from cradle to grave
- 1 May 2015
- journal article
- case report
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 18, 16-20
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial HypercholesterolemiaCirculation, 2013
- Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis SocietyEuropean Heart Journal, 2013
- Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemiaJournal of Clinical Lipidology, 2012
- Reduction in Mortality in Subjects With Homozygous Familial Hypercholesterolemia Associated With Advances in Lipid-Lowering TherapyCirculation, 2011
- Fatal Myocardial Infarction at 4.5 Years in a Case of Homozygous Familial Hypercholesterolaemia2011
- Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genesNetherlands Heart Journal, 2011
- Efficacy criteria and cholesterol targets for LDL apheresisAtherosclerosis, 2010
- LDL-Apheresis in Homozygous LDL-Receptor-Defective Familial Hypercholesterolemia: The Munich ExperienceAtherosclerosis Supplements, 2009
- Recommendations for the use of LDL apheresisAtherosclerosis, 2008
- Efficacy and Safety of Ezetimibe Coadministered With Atorvastatin or Simvastatin in Patients With Homozygous Familial HypercholesterolemiaCirculation, 2002